Rhinomed Ltd
ASX:RNO
Rhinomed Ltd
ASX:RNO
Price:
0.04 AUD
Market Closed
Updated:
Apr 30, 2024
Rhinomed Ltd
Operating Income
|
Rhinomed Ltd
Operating Income Peer Comparison
Comparables:
MYX
NEU
BOT
PBP
C
CU6
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Rhinomed Ltd
ASX:RNO
|
Operating Income
-AU$8.5m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-6%
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Operating Income
-AU$165.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Operating Income
AU$204.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
102%
|
CAGR 10-Years
N/A
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Operating Income
-AU$18.3m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-28%
|
|
|
Probiotec Ltd
ASX:PBP
|
Operating Income
AU$20m
|
CAGR 3-Years
31%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Operating Income
-AU$26.4m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Rhinomed Ltd's Operating Income?
Operating Income
-8.5m
AUD
-8.5m
AUD
Based on the financial report for Jun 30, 2023, Rhinomed Ltd's Operating Income amounts to -8.5m AUD.
What is Rhinomed Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-6%
-6%
Over the last year, the Operating Income growth was -41%. The average annual Operating Income growth rates for Rhinomed Ltd have been -2% over the past three years , -15% over the past five years , and -6% over the past ten years .
You don't have any saved screeners yet
